Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Predicting Clinical Sensitivities of PDGFRA Exon 18 Mutations to Imatinib and Avapritinib to Optimize Gastrointestinal Stromal Tumor Treatment.

Cancer research communications·2026
Same author

Deep Learning Predicts Mutations and Outcomes in Gastrointestinal Stromal Tumors from Whole-Slide Images.

Cancer research·2026
Same author

Detection of Gene Fusions in Soft Tissue Sarcoma Using Next-Generation Sequencing.

Genes·2026
Same author

MONETTE: A Randomized Phase II Study of Ceralasertib plus Durvalumab or Ceralasertib Monotherapy in Patients with Advanced Melanoma Resistant to PD-(L)1 Inhibition.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Desmoid Tumors-Biology-Driven Management and Treatment Selection.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026
Same author

Integrated Immune and Molecular Profiling Identifies Prognostic Subgroups and Therapeutic Targets in Chondrosarcoma.

International journal of molecular sciences·2026

Related Experiment Video

Updated: Jun 27, 2025

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

14.3K

Establishing biomarkers for soft tissue sarcomas.

Anna M Czarnecka1,2, Paulina Chmiel1,3, Piotr Błoński1,3

  • 1Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.

Expert Review of Anticancer Therapy
|April 29, 2024
PubMed
Summary

New biomarkers for soft tissue sarcomas (STS) show promise. Research in genomics and proteomics could improve prognosis and personalize treatment for this rare cancer.

Keywords:
BiomarkerSTSgeneticsprognosissarcoma

More Related Videos

Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures
06:32

Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures

Published on: January 9, 2019

7.9K
Establishment of a Clinic-based Biorepository
07:50

Establishment of a Clinic-based Biorepository

Published on: May 29, 2017

6.5K

Related Experiment Videos

Last Updated: Jun 27, 2025

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

14.3K
Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures
06:32

Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures

Published on: January 9, 2019

7.9K
Establishment of a Clinic-based Biorepository
07:50

Establishment of a Clinic-based Biorepository

Published on: May 29, 2017

6.5K

Area of Science:

  • Oncology
  • Genomics
  • Proteomics

Background:

  • Soft tissue sarcomas (STS) are rare, diverse tumors with limited curative options for advanced stages.
  • Current prognosis relies on histology and clinical features; few biomarkers are clinically established.
  • Advanced STS stages carry a poor prognosis, necessitating improved prognostic tools.

Purpose of the Study:

  • To review recent research on novel biomarkers for soft tissue sarcomas.
  • To explore the potential of genomic, proteomic, and clinical data in improving STS patient outcomes.
  • To highlight the need for validated biomarkers for personalized treatment strategies.

Main Methods:

  • Comprehensive literature search of PubMed, Scopus, and clinicaltrials.gov databases (up to November 2023).
  • Analysis of recent research focusing on genomic, proteomic, and clinical characteristic-based biomarkers.
  • Review of studies investigating biomarker utility in prognosis, recurrence prediction, and treatment response.

Main Results:

  • Novel potential biomarkers identified through recent genomic and proteomic research.
  • Genomic and proteomic profiling offers new avenues for understanding STS.
  • Clinical characteristics combined with molecular data show potential for improved prediction.

Conclusions:

  • Defining prognostic markers for STS remains a significant challenge.
  • Further studies are essential for validating new biomarkers.
  • Personalized treatment for STS requires advanced genetic profiling and analysis of individual tumor/patient characteristics.